GENETICS
Spitomics
The first stop on the road to a healthcare revolution: saliva-collection parties. But as the nascent direct-to-consumer genetic testing industry grows, what can consumers really expect to learn from these services?
GENETICS
The first stop on the road to a healthcare revolution: saliva-collection parties. But as the nascent direct-to-consumer genetic testing industry grows, what can consumers really expect to learn from these services?
The Genetic Information Non-discrimination Act (H.R. 493) moved another step closer to becoming law yesterday. Although the House passed the bill last year, a reconciled version had go through again, as the Senate added an amendment when it passed the bill last week.
Scientists at the J. Craig Venter Institute in Rockville, Maryland have succeeded in synthesizing the complete genome of a bacterium, Mycoplasma genitalium. If the stitched DNA can be inserted into a cell that then replicates, it will appear to have met the criteria for the first “artificial life” form.
Healthcare professionals helping patients with mental health problems have an increasing array of treatment and prevention tools at their disposal. But on the horizon is a preventative tool that poses challenging public policy questions about ethics and privacy: personal genomic sequencing.
J. Craig Venter recently announced his institutes’s goal of sequencing the genomes of up to 50 people by the end of 2008, with an ultimate goal of sequencing 10,000 people’s genomes within ten years. Personalized genome sequencing will open the door to powerful new therapies, but it also poses ethical concerns over the possibility of genetic discrimination.
The Guardian reported this past weekend that J. Craig Venter will soon announce that he has created artificial life. But even his spokesperson is saying that’s not the whole story.